NSE · TORNTPHARM
Torrent Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹4,145 Cr with net profit ₹498 Cr — a 12.01% net margin, versus 11.83% the period before.
Shareholding
As of 2026-09-30
- Promoter60.78%
- Public8.54%
- FII17.22%
- DII13.46%
1,42,140 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.49× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited(this company) | ₹1,80,675 Cr | 83.22 | 9.81 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹52,297 Cr | 45.64 | 5.05 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹41,333 Cr | 32.73 | 8.51 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,468 Cr | 95.31 | 19.38 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹18,431 Cr | 64.81 | 6.68 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,110 Cr | 27.22 | 5.37 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹17,122 Cr | 22.87 | 4.12 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,764 Cr | 24.59 | 4.13 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹6,535 Cr | 40.17 | 4.97 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,347 Cr | 40.06 | 5.32 | 13.31% | 18.57% |
AI analysis
AI-generated · google/gemini-2.5-flashTorrent Pharmaceuticals Limited is listed with a market capitalization of Rs 169405 Cr. The company reported revenue of Rs 13886.15 Cr and a profit margin of 15.55%. Its earnings per share (EPS) currently stand at Rs 64.76.
Positives
- +Revenue grew 21.4% to Rs 13886.15 Cr.
- +The return on equity (ROE) is 25.49%.
- +Promoter holding is 60.7794% as of July 31, 2026.
Negatives
- −The number of shareholders increased from 36530 in September 2019 to 140599 in July 2026, indicating increased dispersion.
- −Promoter pledge data is unavailable for periods prior to July 31, 2026, except for September 2019, which showed 36.49%.
Financial performance
For the period ending March 2026, Torrent Pharmaceuticals Limited recorded revenue of Rs 13886.15 Cr, showing a revenue growth of 21.4%. The company's net profit for the same period was Rs 2163.37 Cr. The latest quarterly revenue for March 2026 was Rs 4197 Cr, with a net profit of Rs 364 Cr.
Profitability & returns
The company's profit margin was 15.55%. Return on equity (ROE) was 25.49%, while return on capital employed (ROCE) stood at 13.8466%. The earnings per share (EPS) for the latest period was Rs 64.76.
Balance sheet
Torrent Pharmaceuticals Limited has a debt-to-equity ratio of 1.14. The book value per share is Rs 247.85. No data on pledged shares by promoters was available for the recent periods.
Ownership & pledges
As of July 31, 2026, promoter holding was 60.7794%. FIIs held 17.9709%, and DIIs held 12.8674%. The public shareholding was 8.38229999999999%. The number of shareholders was 140599. There were no reported promoter pledges.
Regulatory & surveillance
No information regarding surveillance measures for Torrent Pharmaceuticals Limited was available in the provided data.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Torrent Pharmaceuticals Limitedshare price & fundamentals